Final Set of Interim Data from PXS-5505 in Myelofibrosis
Filed with ASX · · 3 pages · English
Story so far
Earlier from Syntara
- PXS Announces Encouraging Results from Phase 1c Scar Study
- After FDA Review PXS Accelerates Plans for Combination Study
- PXS announces positive interim data from myelofibrosis trial
- Investor Presentation
- PXS Releases Promising Interim Data from Skin Scarring Study
Later from Syntara
- PXS to Receive Prepayment of 2023 Research Tax Incentive
- PXS Company Restructure Sale of Mannitol Business
- Half Yearly Report and Accounts
- Appendix 4E and Annual Report to shareholders
- Pause in Trading
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara